Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
--
P/B Ratio
7.81
Industry P/E
--
Debt to Equity
0
ROE
-3.71 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-97.76 Mln
EBITDA
$8,290,586.27 Mln
Net Profit
$8,290,563.01 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| 32.35 | 33.69 | -21.33 | -93.80 | -82.67 | -60.10 | -58.81 |
|
BSE Sensex*
| 2.47 | 4.26 | 4.78 | 8.73 | 11.92 | 20.27 | 11.20 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| -97.53 | -72.98 | -60.16 | 85.59 | -79.83 | -68.43 | -65.82 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a... DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Read more
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kintara Therapeutics Inc (KTRA) stood at $ 12 Mln as on 30-Sep-24
The share price of Kintara Therapeutics Inc (KTRA) is $0.23 (NASDAQ) as of 17-Oct-2024 19:49 EDT. Kintara Therapeutics Inc (KTRA) has given a return of -82.67% in the last 3 years.
Kintara Therapeutics Inc (KTRA) has a market capitalisation of $ 12 Mln as on 18-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kintara Therapeutics Inc (KTRA) is 7.81 times as on 18-Oct-2024, a 255% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of Kintara Therapeutics Inc (KTRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kintara Therapeutics Inc (KTRA) and enter the required number of quantities and click on buy to purchase the shares of Kintara Therapeutics Inc (KTRA).
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
The CEO & director of Mr. Robert E. Hoffman B.B.A., CPA. is Kintara Therapeutics Inc (KTRA), and CFO & Sr. VP is Mr. Robert E. Hoffman B.B.A., CPA.
There is no promoter pledging in Kintara Therapeutics Inc (KTRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Kintara Therapeutics Inc. (KTRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-162.48
|
|
Operating margin(%)
|
-7150
|
|
Net Margin(%)
|
-10346.05
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kintara Therapeutics Inc (KTRA) was $0 Mln.
$-7.82
(
